AGTC

AGTC is a clinical-stage AAV gene therapy company developing therapies for ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs.  AGTC has active clinical trials in X-linked retinitis pigmentosa and achromatopsia and preclinical efforts in optogenetics, otology and CNS disorders. Our product pipeline leverages our industry leading AAV research and development expertise as well as a scalable and cost-efficient manufacturing technology.